TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00443924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS115644 Ophthalmic Solution
Description: One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop of placebo in each eye every 12 hours for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS115644 Ophthalmic Solution
Description: One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS115644 Ophthalmic Solution
Description: One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS115644 Ophthalmic Solution
Description: One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
Study: NCT02234505

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prosthetic alignment perturbation
Description: Prosthetic ankle plantar-flexion will be modified in different degrees, devices (prosthetic components) will not be modified from baseline condition
Study: NCT03832270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents InC
Description: Based on social learning theory, Parents InC has been designed specifically for parents of children with an ADHD diagnosis with a particular focus on parenting sense of self competence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incredible Years
Description: Also based on social learning theory but focus is not specifically on ADHD.
Study: NCT02574845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Study: NCT00657735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-Coil deep TMS
Description: 20 daily deep rTMS treatments

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: inactive treatment
Study: NCT01399697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: orally, Week 1 - 16

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: orally, Week 1 - 16
Study: NCT01405495

Intervention type: PROCEDURE
Intervention: MRI-based techniques (sMRI, fMRI, DTI, ASL)
Description: no drugs include

Intervention type: PROCEDURE
Intervention: MRI-based techniques (sMRI, fMRI, DTI, ASL)
Description: no drugs include

Intervention type: PROCEDURE
Intervention: MRI-based techniques (sMRI, fMRI, DTI, ASL)
Description: no drugs include
Study: NCT01439646

Intervention type: OTHER
Intervention: it is a retrospective study, hence no active intervention
Description: since it is an observational restrospective study hence no active intervention is planned
Study: NCT03450759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 Oral suspension (reference)
Description: Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 Oral suspension (reference)
Description: Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 Oral suspension (reference)
Description: Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 Oral suspension (reference)
Description: Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 capsule
Description: Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 capsule
Description: Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 capsule
Description: Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 capsule
Description: Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
Study: NCT01399697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: orally, Week 17-28

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: methotrexate placebo orally, Week 17-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 28 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 28 weeks
Study: NCT03988738

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Social Media Publications
Description: Messages will be elaborated prior to participant enrollment. Messages will be evaluated by three experts.
Study: NCT03450759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 ER capsule (fastvrate)
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 ER capsule (fastvrate)
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 ER capsule (fastvrate)
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 ER capsule (fastvrate)
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 ER capsule (Int. rate)
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 ER capsule (Int. rate)
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 ER capsule (Int. rate)
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 ER capsule (Int. rate)
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
Study: NCT04508686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, camrelizumab
Description: This is a single-arm study with all patients receiving these two drugs.
Study: NCT00356109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable insulin
Description: patient specific dose, injected, before meals, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: patient specific dose, injectable, before meals, 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: patient specific dose, injectable, before meals, 6 months
Study: NCT03782181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration platform
Description: A neuromuscular treatment using a rotational whole body vibration platform.
Study: NCT04284683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DRINK - Water, Protein, Fat, Carbohydrate
Description: Following exercise participants will consume a drink (with different composition in each visit) and than RMR will be evaluated.
Study: NCT02676557

Intervention type: DEVICE
Intervention: Exposed to the high pressure during the surgery
Study: NCT03875469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centargo injector (BPI 1000045)
Description: Contrast-enhanced computer tomography conducted with Centargo injector

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centargo injector (BPI 1000045)
Description: Contrast-enhanced computer tomography conducted with Centargo injector

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellant MP injector
Description: Contrast-enhanced computer tomography conducted with Stellant MP injector
Study: NCT01510821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Maquet Vasoshield Pressure-limiting syringe on SVG
Description: Use of Maquet Vasoshield Pressure-limiting syringe on SVG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of non-regulated syringe on SVG
Description: Use of non-regulated syringe on SVG
Study: NCT01921517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Magnitude Mechanical Stimulation
Description: Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Low Magnitude Mechanical Stimulation
Description: Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
Study: NCT00500448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks
Study: NCT01754324

Intervention type: DRUG
Intervention: Methadone
Description: The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
Study: NCT04221269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Treatment as Usual
Description: Routine community care plus assessment feedback reports to clinicians.
Study: NCT03988738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Media Publications
Description: Messages will be elaborated prior to participant enrollment. Messages will be evaluated by three experts.
Study: NCT02579135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer Sex
Description: Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Growth Mindsets
Description: Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
Study: NCT02812940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: GvHD prophylaxis
Study: NCT01921153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy meal plates and trays
Description: The healthy meal plates and trays provide guidance for how to construct a meal in the military dining facility.
Study: NCT04221269

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: Routine community care plus assessment feedback reports to clinicians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Long-term with Active Suicide Program for Schizophrenia
Description: Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
Study: NCT02963155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Study: NCT01301040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin, cyclophosphamide, docetaxel
Description: * Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.~* Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin, cyclophosphamide, docetaxel
Description: * Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.~* Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
Study: NCT04646291

Intervention type: DEVICE
Intervention: Insemination with the Mosie Baby Kit
Description: The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.

Intervention type: DEVICE
Intervention: Insemination with the Mosie Baby Kit
Description: The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.

Intervention type: DEVICE
Intervention: Insemination with the Mosie Baby Kit
Description: The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.
Study: NCT02179567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks
Study: NCT02687438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steroid-releasing sinus implant
Description: PROPEL (Intersect ENT, Menlo Park, CA) containing 370mcg of mometasone furoate designed for gradual release over 30 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-op standard of care
Description: post-op standard of care including debridement, irrigation, and/or topical steroids
Study: NCT03461159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operant conditioning of H-reflexes
Description: Spinal reflex responses will be elicited in a wrist flexor muscle using a peripheral nerve stimulator. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to decrease the size of the H-reflex response over successive trials. Responses that are below a threshold will be rewarded and those above will not.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operant conditioning of H-reflexes
Description: Spinal reflex responses will be elicited in a wrist flexor muscle using a peripheral nerve stimulator. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to decrease the size of the H-reflex response over successive trials. Responses that are below a threshold will be rewarded and those above will not.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operant conditioning of motor evoked potentials
Description: Motor evoked potentials will be elicited in a wrist flexor muscle using transcranial magnetic stimulation. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to increase the size of the MEP response over successive trials. Responses that are above a threshold will be rewarded and those below will not.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operant conditioning of motor evoked potentials
Description: Motor evoked potentials will be elicited in a wrist flexor muscle using transcranial magnetic stimulation. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to increase the size of the MEP response over successive trials. Responses that are above a threshold will be rewarded and those below will not.
Study: NCT04091061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 100 mg
Description: PF-06865571 in 100 mg oral tablet will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 100 mg
Description: PF-06865571 in 100 mg oral tablet will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 100 mg
Description: PF-06865571 in 100 mg oral tablet will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 100 mg
Description: PF-06865571 in 100 mg oral tablet will be administered on Day 1
Study: NCT00742326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 45 mg/daily
Study: NCT00988104

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Description: Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
Study: NCT00775762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: Aspirin (75-100 mg)die for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Clopidogrel (75mg) die for three months
Study: NCT00742326

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule daily
Study: NCT01693900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-operative Ultrasound FICB Group
Description: Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under ultrasound guidance with an in-plane technique by a single study investigator in the preoperative area. Although possible without ultrasound guidance, using this technique allows for identification of specific tissue planes and precise placement of medication near the nerves responsible for postoperative pain. Using ultrasound, the superficial fascial layer of the iliopsoas muscle is identified at the anterior edge of the ilium, and a needle is placed just beneath that fascia. A high volume of local anesthetic is then injected under ultrasound guidance, ensuring cephalad spread of medication in an attempt to provide anesthesia of the lateral femoral cutaneous, femoral and obturator nerves.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative FICB Group
Description: Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room. Unlike other approaches to hip replacement, anterior repair allows for direct visualization of the fascial layers described above. This allows for direct injection of local anesthetic beneath this fascia, potentially obviating the need for preoperatively performed, ultrasound guided, FICB.
Study: NCT00310557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist)
Description: Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
Study: NCT02338453

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Attention Bias Modification Treatment
Description: Attention bias is modified using a dot-probe task. Each trial begins with a fixation cross presented in the center of the screen for 500 ms. Next, participants are presented with two stimuli depicting two faces of the same individual for 500 ms, either of two neutral faces or with one neutral face and one disgust face (i.e., the socially-threatening stimulus). Then, one of two optional probes appears in the location former occupied by one of the faces. Participants are instructed to discriminate as fast as possible between the two variants of the probe, without compromising accuracy, by pressing on two corresponding keys. The probe remains on the screen until the participant responds, after which the next trial commences. This protocol is designed to divert attention away from socially-threatening stimuli as in 80% of trials the probe appears in the location formerly occupied by the neutral face. The remaining 20% of trials include two neutral faces, with no predictive value

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Attention Bias Modification Treatment
Description: the Placebo ABMT is similar to the active ABMT except that this protocol is not designed to divert attention away from or toward socially-threatening stimuli as in 40% of trials the probe appears in the location formerly occupied by the neutral face and in 40% it appears in the location formally occupied by the threatening face. The remaining 20% of trials include two neutral faces
Study: NCT00775762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel plus aspirin
Description: clopidogrel 75 mg die plus aspirin 75-100 mg for three months
Study: NCT00983645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
Study: NCT00825539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02712749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound with Binaural Beats
Description: Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz generated by the special program Gnaural in stereo option

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sound without Binaural Beats
Description: Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the program Gnaural in mono option
Study: NCT00657462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Users of the PAML Builder application will receive reminders about three application features (copy/paste, audit trail, sort medications by class) at the startup of the application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reminders
Description: Users of the PAML Builder application will receive reminders about three application features (copy/paste, audit trail, sort medications by class) at the startup of the application
Study: NCT03530748

Intervention type: PROCEDURE
Intervention: Endovascular therapy and Imaging Acquisition
Description: 1. Endovascular repair for renal artery stenosis;~2. Parenchymal Blood Volume(PBV) acquisition and analysis for target kidney